Equity Profile

MRNA

Moderna, Inc.

Health CareBiotechnology$23.0B

Jul31Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of profitability and financial health.

$-2.04

Revenue

Revenue figures provide insight into the company's sales performance and market demand.

$104M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics. With a market cap of $23 billion, it plays a significant role in the health care sector, especially in the context of vaccine development and infectious disease management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of $-3.40, which was worse than the expected $-3.02, leading to a stock decline of 1.24% the following day. The company continues to face challenges in revenue generation amid a competitive landscape.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Moderna to report a loss this quarter, with a consensus EPS of $-2.04 and revenue of $104 million. The market is closely watching how the company navigates its post-COVID vaccine landscape.

Bull Case

If Moderna can exceed revenue expectations and show signs of recovery in its vaccine sales or new product developments, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger-than-expected loss or disappointing revenue, it could further erode investor confidence and lead to a significant stock decline.

Key Metrics to Watch

EPS

$-2.04

Earnings per share is a crucial indicator of profitability and financial health.

Revenue

$104M

Revenue figures provide insight into the company's sales performance and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Moderna's revenue exceed the consensus estimate of $104 million?

This figure is critical for assessing the company's ability to recover from recent losses and indicates market demand for its products.

What updates will management provide regarding future product development or pipeline advancements?

Insights into new products or developments could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic about Moderna's revenue potential, underestimating the impact of new product developments in its pipeline.

Supporting Evidence

The company has a history of surprising on the upside, with a 75% EPS beat rate.

Options are pricing a 16.5% move, indicating expectations for volatility that may not materialize if results are better than feared.

Key Risk

If revenue comes in above $104 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Moderna's ability to recover from recent financial struggles and its future growth potential.

Bull Confirmed If

Revenue exceeding $104 million and positive commentary on future product developments would confirm the bull case.

Bear Confirmed If

A larger-than-expected loss or revenue below $75 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats expectations, history suggests a potential stock increase of around 4.55%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 1.06%, which could heighten concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product launches or pipeline advancements.
2Updates on vaccine sales and market demand.
3Management's outlook on future revenue growth.
4Any changes in operational strategy or cost management.
5Insights into competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul28

KNSABMO

Kiniksa Pharmaceuticals International, plc

PreviewView

Jul28

CURBBMO

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of profitability and financial health.

$-2.04

Revenue

Revenue figures provide insight into the company's sales performance and market demand.

$104M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Moderna can exceed revenue expectations and show signs of recovery in its vaccine sales or new product developments, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger-than-expected loss or disappointing revenue, it could further erode investor confidence and lead to a significant stock decline.

Key Metrics to Watch

EPS

$-2.04

Earnings per share is a crucial indicator of profitability and financial health.

Revenue

$104M

Revenue figures provide insight into the company's sales performance and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Moderna's revenue exceed the consensus estimate of $104 million?

This figure is critical for assessing the company's ability to recover from recent losses and indicates market demand for its products.

What updates will management provide regarding future product development or pipeline advancements?

Insights into new products or developments could significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic about Moderna's revenue potential, underestimating the impact of new product developments in its pipeline.

Supporting Evidence

The company has a history of surprising on the upside, with a 75% EPS beat rate.

Options are pricing a 16.5% move, indicating expectations for volatility that may not materialize if results are better than feared.

Key Risk

If revenue comes in above $104 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Moderna's ability to recover from recent financial struggles and its future growth potential.

Bull Confirmed If

Revenue exceeding $104 million and positive commentary on future product developments would confirm the bull case.

Bear Confirmed If

A larger-than-expected loss or revenue below $75 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats expectations, history suggests a potential stock increase of around 4.55%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of around 1.06%, which could heighten concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product launches or pipeline advancements.
2Updates on vaccine sales and market demand.
3Management's outlook on future revenue growth.
4Any changes in operational strategy or cost management.
5Insights into competitive positioning in the biotechnology sector.